The US Food and Drug Administration has approved two new breakthrough therapies for patients with sickle cell disease (SCD), and we believe both may enhance the treatment of our patients here at CHOP. “This is truly an exciting time for sickle cell disease,” said pediatric hematologist Dr. Kim Smith-Whitley, Director of the Comprehensive Sickle Cell Center, and leader of our new CuRed Frontier Program. “These two new agents address different pathways, so we hope there will be synergy.”
Dr. Smith-Whitley was featured in this story in the Philadelphia Inquirer. Read more here.
Contact: Amy Burkholder, The Children’s Hospital of Philadelphia, 267-426-6083